Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade.
T-cell infiltration
biomarker
collagen
extracellular matrix
fibrosis
immune checkpoint inhibitor
immunotherapy
ipilimumab
melanoma
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Sep 2020
28 Sep 2020
Historique:
received:
04
08
2020
revised:
23
09
2020
accepted:
26
09
2020
entrez:
1
10
2020
pubmed:
2
10
2020
medline:
2
10
2020
Statut:
epublish
Résumé
A T-cell permissive tumor microenvironment, characterized by the presence of activated T cells and low fibrotic activity is crucial for response to immune checkpoint inhibitors (ICIs). Granzyme B has been shown to promote T-cell migration through the basement membrane by the degradation of type IV collagen. In this study, we evaluated the biomarker potential of measuring granzyme B-mediated degradation of type IV collagen (C4G) in combination with a fibroblast activation biomarker (PRO-C3) non-invasively for identifying metastatic melanoma patients responding to the ICI ipilimumab. A monoclonal antibody was generated against C4G and used to develop a competitive electro-chemiluminescence immunoassay. C4G and PRO-C3 were measured in pretreatment serum from metastatic melanoma patients (
Identifiants
pubmed: 32998446
pii: cancers12102786
doi: 10.3390/cancers12102786
pmc: PMC7601429
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
BMC Musculoskelet Disord. 2018 Nov 29;19(1):416
pubmed: 30497455
Nat Commun. 2018 Aug 29;9(1):3503
pubmed: 30158554
PLoS One. 2017 Jul 13;12(7):e0175582
pubmed: 28704418
Trends Biochem Sci. 2000 Mar;25(3):147-50
pubmed: 10694887
Sci Rep. 2016 Jul 28;6:30599
pubmed: 27465284
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
J Immunother Cancer. 2018 Dec 19;6(1):152
pubmed: 30567561
Somatic Cell Genet. 1977 Mar;3(2):231-6
pubmed: 605383
Clin Cancer Res. 2014 Jul 1;20(13):3422-33
pubmed: 24763614
Nat Commun. 2018 Nov 8;9(1):4692
pubmed: 30410077
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Biomarkers. 2011 May;16(3):193-205
pubmed: 21506694
J Clin Oncol. 2007 Apr 20;25(12):1562-9
pubmed: 17443000
Dev Immunol. 2000;7(2-4):171-7
pubmed: 11097210
J Immunother Cancer. 2018 Mar 6;6(1):18
pubmed: 29510697
Cancer Res. 2017 May 1;77(9):2318-2327
pubmed: 28461564
Matrix Biol. 2015 May-Jul;44-46:200-6
pubmed: 25652204
Cancer Biomark. 2015;15(6):783-8
pubmed: 26406420
Immunity. 2014 Dec 18;41(6):960-72
pubmed: 25526309
Semin Cancer Biol. 2019 Dec;59:290-297
pubmed: 31430555
Clin Biochem. 2010 Jul;43(10-11):793-804
pubmed: 20381482
Cancer Immunol Res. 2018 Sep;6(9):990-1000
pubmed: 30181337
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Clin Invest. 2012 Mar;122(3):899-910
pubmed: 22293174
J Exp Clin Cancer Res. 2019 Mar 6;38(1):115
pubmed: 30841909
J Immunother Cancer. 2018 Jul 3;6(1):65
pubmed: 29970158
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
J Immunother Cancer. 2019 Mar 12;7(1):68
pubmed: 30867051
Cancer Immunol Immunother. 2018 Jan;67(1):1-12
pubmed: 29022089
Oncoimmunology. 2015 Nov 25;5(4):e1100788
pubmed: 27141381
Am J Transl Res. 2013 Apr 19;5(3):303-15
pubmed: 23634241
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
J Transl Med. 2011 Nov 28;9:204
pubmed: 22123319
NPJ Precis Oncol. 2018 Nov 15;2:25
pubmed: 30456308